A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC) worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC treated with Nivolumab is still under debate. This meta-analysis was to assess the significance of NLR as a predictive factor in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Dedong, Xu, Huilin, Xu, Ximing, Guo, Tao, Ge, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205035/
https://www.ncbi.nlm.nih.gov/pubmed/30377569
http://dx.doi.org/10.1080/2162402X.2018.1507262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205035/
https://www.ncbi.nlm.nih.gov/pubmed/30377569
http://dx.doi.org/10.1080/2162402X.2018.1507262

Ejemplares similares